Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management

NCT07371585 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

300

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer Stage IV

Interventions

DEVICE: Digital Health Tools
DRUG: T-DXd
DRUG: Pertuzumab

Sponsor

SOLTI Breast Cancer Research Group

Collaborators

[object Object]
[object Object]